InvestorsHub Logo
icon url

rafunrafun

03/07/21 7:08 PM

#328581 RE: Number sleven #328579

N - I can't get that link to open but I heard from a friend in the business that that is true.

He will confirm tomorrow if UHC no longer covers gV or just don't cover V / gV for VHTG.

If the former, this is monumental.
icon url

ggwpq

03/07/21 7:09 PM

#328582 RE: Number sleven #328579

NS, if I read your link correctly, V is not covered by UNH for any indications, including cardiovascular risk reduction.
icon url

Monk44

03/07/21 7:27 PM

#328587 RE: Number sleven #328579

White Flag?
icon url

dukesking

03/07/21 7:42 PM

#328590 RE: Number sleven #328579

I hate to rain on the parade but it looks UHC is removing Vascepa and GV from coverage. Might be just a precaution until the suits are settled or it might be a salvo from the health insurance industry in response to AMRN’s suit against HN. GSK/Teva and AMRN/Hikma/HN cases have shed light on infringement issues and muddied the waters for payers. I don’t see this as good news for scripts or near term growth.
icon url

rafunrafun

03/07/21 7:58 PM

#328591 RE: Number sleven #328579

N - this is only for VHTG, not for ACVD.

I am confirming that UHC still cover V for ACVD.
icon url

dukesking

03/07/21 8:11 PM

#328595 RE: Number sleven #328579

Sleven, I reread the link thought provide and it’s only referring to the UHC Commercial plans. Still not good but I’m hoping Vascepa is still on their Medicare plans and others.